Iwatsuki et al., 199133 Iwatsuki K, Takigawa M, Hashimoto T, Nishikawa T, Yamada M. Can pemphigus vulgaris become pemphigus foliaceus? J Am Acad Dermatol. 1991;25:797-800.
|
2/31 |
36‒58/F |
NA |
CS, AZA |
1‒3 |
Hp, IB/Dsg1+ (n = 1) |
5‒6/- |
Hashimoto et al., 199144 Hashimoto T, Konohana A, Nishikawa T. Immunoblot assay as an aid to the diagnoses of unclassified cases of pemphigus. Arch Dermatol. 1991;127:843-7.
|
3/NA |
NA |
NA |
NA |
3‒20 |
Hp, IB/Dsg1+
|
NA |
Kawana et al.,199455 Kawana S, Hashimoto T, Nishikawa T, Nishiyama S. Changes in clinical features, histologic findings, and antigen profiles with development of pemphigus foliaceus from pemphigus vulgaris. Arch Dermatol. 1994;130:1534-8.
|
2/NA |
46‒57/F |
Dsg3+
|
CS |
3 |
Hp, IB/Dsg1+
|
NA |
Chang et al., 199766 Chang SN, Kim SC, Lee IJ, Seo SJ, Hong CK, Park WH. Transition from pemphigus vulgaris to pemphigus foliaceus. Br J Dermatol. 1997;137:303-5.
|
1/NA |
47/M |
NA |
CS |
3 |
Hp, IB/Dsg1+, Dsg3+
|
NA |
Mendiratta et al., 200077 Mendiratta V, Sarkar R, Sharma RC, Korann RV. Transition of pemphigus vulgaris to pemphigus foliaceus. Indian J Dermatol Venereol Leprol. 2000;66:85-6.
|
1/NA |
46/F |
NA |
CS, CYC |
NA |
Hp |
NA |
Komai et al., 200188 Komai A, Amagai M, Ishii K, Nishikawa T, Chorzelski T, Matsuo I, et al. The clinical transition between pemphigus foliaceus and pemphigus vulgaris correlates well with the changes in autoantibody profile assessed by an enzyme-linked immunosorbent assay. Br J Dermatol. 2001;144:1177-82.
|
4/NA |
38‒65/NA |
Dsg1+, Dsg3+ (n = 3), Dsg3+ (n = 3) |
NA |
0.5‒1 |
Hp, ELISA, IB/Dsg1+ (n = 4), Dsg1+ (n = 3) |
NA/Yes (n = 1) |
Kimoto et al., 200199 Kimoto M, Ohyama M, Hata Y, Amagai M, Nishikawa T. A case of pemphigus foliaceus which occurred after five years of remission from pemphigus vulgaris. Dermatology. 2001;203:174-6.
|
1/NA |
77/F |
Dsg3+
|
CS |
5 |
Hp, ELISA/Dsg1+
|
NA |
Tsuji et al., 20021010 Tsuji Y, Kawashima T, Yokota K, Tateish Y, Tomita Y, Matsumura T, et al. Clinical and serological transition from pemphigus vulgaris to pemphigus foliaceus demonstrated by desmoglein ELISA system. Arch Dermatol. 2002;138:95-6.
|
1/NA |
55/M |
Dsg3+
|
CS, PHP |
3 |
Hp, ELISA/Dsg1+
|
NA |
Harman et al., 20021111 Harman KE, Gratian MJ, Shirlaw PJ, Bhogal BS, Challacombe SJ, Black MM. The transition of pemphigus vulgaris into pemphigus foliaceus: a reflection of changing desmoglein 1 and 3 autoantibody levels in pemphigus vulgaris. Br J Dermatol. 2002;146:684-7.
|
1/NA |
44/F |
Dsg3+, Dsg1+
|
CS, CYC AZA, MMF |
5 |
ELISA/Dsg1+
|
4/- |
Tóth et al., 20021212 Tóth GG, Pas HH, Jonkman MF. Transition of pemphigus vulgaris into pemphigus foliaceus confirmed by antidesmoglein ELISA profile. Int J Dermatol. 2002;41:525-7.
|
1/NA |
28/M |
Dsg3+, Dsg1+
|
CS |
2 |
Hp, ELISA/Dsg1+
|
NA |
Ng et al., 20051313 Ng PP, Thng ST. Three cases of transition from pemphigus vulgaris to pemphigus foliaceus confirmed by desmoglein ELISA. Dermatology. 2005;210:319-21.
|
3/NA |
29, 56/M |
NA |
CS, AZA |
2‒4 |
ELISA/Dsg1+
|
1‒7/- |
45/F |
Levy-Sitbon et al., 20121414 Lévy-Sitbon C, Reguiaï Z, Durlach A, Goeldel AL, Grange F, Bernard P. Transition from pemphigus vulgaris to pemphigus foliaceus: a case report. Ann Dermatol Venereol. 2013;140:788-92.
|
1/NA |
47/M |
Dsg3+, Dsg1+
|
CS, rituximab |
2.7 |
Hp, ELISA/Dsg1+
|
NA |
Espana et al., 20141515 España A, Koga H, Suárez-Fernández R, Ohata C, Ishii N, Irarrazaval I, et al. Antibodies to the amino-terminal domain of desmoglein 1 are retained during transition from pemphigus vulgaris to pemphigus foliaceus. Eur J Dermatol. 2014;24:174-9.
|
2/NA |
35, 49/M |
Dsg3+, Dsg1+
|
CS, AZA, CYC, rituximab |
2‒3.8 |
Hp, ELISA, IB-IP/Dsg1+ (n = 2), Dsg3+ (n = 1) |
NA |
Ito et al., 20161616 Ito T, Moriuchi R, Kikuchi K, Shimizu S. Rapid transition from pemphigus vulgaris to pemphigus foliaceus. J Eur Acad Dermatol Venereol. 2016;30:455-7.
|
1/NA |
57/M |
Dsg3+, Dsg1+
|
CS, IVIG |
0.2 |
Hp, ELISA/Dsg1+
|
NA |
Chapman et al., 20191717 Chapman CM, Kwock J, Cresce N, Privette E, Cropley T, Gru AA. IgG/IgA pemphigus in a patient with a history of pemphigus vulgaris: An example of epitope spreading? J Cutan Pathol. 2019;46:380-2.
|
1/NA |
56/M |
NA |
AZA, rituximab |
1.2 |
Hp/NA |
NA |
Mohammadrezaee et al., 202022 Mohammadrezaee M, Etesami I, Mahmoudi H, Lajevardi V, Tavakolpour S, Balighi K, et al. Transition between pemphigus vulgaris and pemphigus foliaceus: a 10-year follow-up study. J Dtsch Dermatol Ges. 2020;18:1302-4.
|
12/1483 |
24‒79/6M, 6F |
Dsg3+, Dsg1+
|
NA |
0.5‒5.3 |
ELISA/Dsg1+
|
NA/Yes (n = 1) |
Present study, 2022 |
13/453 |
19‒62/6M,7F |
Dsg3+, Dsg1+ (n = 10), NA (n = 3) |
CS, MMF, AZA, PHP, dapsone |
0.3‒13 |
ELISA/Dsg1+
|
2‒21/Yes (n = 1) |